2023
DOI: 10.1186/s12915-023-01779-9
|View full text |Cite
|
Sign up to set email alerts
|

Geroprotector drugs and exercise: friends or foes on healthy longevity?

Christian J. Elliehausen,
Rozalyn M. Anderson,
Gary M. Diffee
et al.

Abstract: Physical activity and several pharmacological approaches individually combat age-associated conditions and extend healthy longevity in model systems. It is tantalizing to extrapolate that combining geroprotector drugs with exercise could extend healthy longevity beyond any individual treatment. However, the current dogma suggests that taking leading geroprotector drugs on the same day as exercise may limit several health benefits. Here, we review leading candidate geroprotector drugs and their interactions wit… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
2
0

Year Published

2024
2024
2024
2024

Publication Types

Select...
4

Relationship

0
4

Authors

Journals

citations
Cited by 4 publications
(2 citation statements)
references
References 211 publications
0
2
0
Order By: Relevance
“…It is time to determine in human studies whether these low these amino acid restricting diets unlike chronic DR, are sustainable over the long-term and what the long-term health consequences might be. It is also important to discover how the diets affect mood, energy, and interact with other healthy-enhancing lifestyle or pharmaceutical interventions such as exercise or geroprotective drugs ( Elliehausen et al, 2023 ). We have reached the “translation stage” of biological aging research.…”
Section: Discussionmentioning
confidence: 99%
“…It is time to determine in human studies whether these low these amino acid restricting diets unlike chronic DR, are sustainable over the long-term and what the long-term health consequences might be. It is also important to discover how the diets affect mood, energy, and interact with other healthy-enhancing lifestyle or pharmaceutical interventions such as exercise or geroprotective drugs ( Elliehausen et al, 2023 ). We have reached the “translation stage” of biological aging research.…”
Section: Discussionmentioning
confidence: 99%
“…A substantial gap in our understanding pertains to the efficacy of various geroprotectors across diverse human tissues. Existing data are largely derived from a limited number of studies, predominantly utilizing mouse models or in vitro cell cultures, which may not accurately reflect the pathological conditions in humans [205,206]. The targeting of epigenetic factors and markers of senescence has been at the core of several clinical trials, but precise clinical trials targeting histones or histone regulatory molecules have not been performed yet (NCT03353597, NCT00242255, NCT06065241, and NCT05392582).…”
Section: Conclusion and Future Perspectivesmentioning
confidence: 99%